Computational *de-novo* design of esterase active sites







- 1. Design of ester hydrolases
- 2. Design of organophosphate binders (with Sridharan Rajagopalan)

Florian Richter Baker Group

Intro to computational de-novo enzyme design

Process divided into 4 steps

- Reaction -> Minimal active site ("Theozyme")
- 2. Place theozyme into a protein scaffold ("Matching")
- 3. Design sequence for the new active site
- 4. Experimental testing



Computational Enzyme Design

Previous achievements



Reaction	k _{cat} (s⁻¹)	K _M (mM)	k _{cat} /K _M (M ⁻¹ s ⁻¹)	k _{cat} / k _{uncat}	reference
Kemp Elimination	0.29	1.8	163	2*10 ⁵	<i>Nature</i> 453(2008), p190
	5*10 ⁻⁵	0.62	0.11	8*10 ³	<i>Science</i> 319(2008), p1387
Diels-Alder	3*10 ⁻⁵	3.5	0.008	n/a	<i>Science</i> 329(2010), p309

Natural enzymes: k_{cat}/K_M up to $10^8 M^{-1}s^{-1}$, k_{cat}/k_{uncat} up to 10^{21}

Design of novel ester hydrolases



New Target reaction: ester hydrolysis



Why ester hydrolysis?

→ Bechmark for computational enzyme design

- •Computational design is a new technique with room for improvement
- •Ester hydrolysis is one of the best studied reactions in (bio)chemistry
- •Large amount of structural and biochemical data on natural esterases exists

→How well can we recreate natural esterases using computational design?

Design of novel ester hydrolases



Reaction mechanism: an ester/amide gets split into an acid an an alcohol/amine



Key features:

•Nucleophilic attack onto ester-carbon

Tetrahedral intermediate

•Catalytic nucleophile binds covalently ('acylenzyme intermediate')

•Negative charge accumulation at esteroxygen

Design of novel ester hydrolases Choice of theozyme

Natural hydrolase active sites:

- •often use Ser or Cys as nucleophile
- •Nucleophile activated by His or other protic residue

•Feature oxyanion-stabilizing elements ("oxyanion-hole")





Design theozyme

- •Cys as nucleophile (higher intrinsic nucleophilicity than Ser)
- •His as proton shuttle (protonate leaving group, deprotonate water)
- •Backbone-NH as oxyanion stabilizer

Design of novel ester hydrolases

•28 designs were tested, 4 had activity

(coloring: scaffold x-ray / design model)



Scaffold: galacturonide binding protein 11 Mutations Catalytic site: E161C / M226H / Q163G



Scaffold: Trp – tRNA synthetase 20 Mutations Catalytic site: Q9C / Y125H



Design of novel ester hydrolases In-detail characterization of 4 active designs



1. Are they active for the right reason?

→ yes, catalytic residue knock-outs suggest activity is due to designed site

- 2. How active are they?
 - → k_{cat}/K_M ~10² M⁻¹ s⁻¹
 - → < natural hydrolases, \approx other computational *de-novo* designs
 - ➔ 2-phase kinetics observed (fast acylation / slow deacylation)
- 3. Does the catalytic mechanism work as designed?
 - ➔ covalent intermediate detected by Mass spectrometry
 - ➔ designs react with nucleophile-specific probe as good as natural cys hydrolases
- 4. Does the structure look as designed?
 - → X-ray structure elucidation
 - ➔ Molecular dynamics simulations

2.5. Does the structure look as designed?

Crystal structures of the 4 designs were determined

(coloring: design x-ray / design model)





•Overall shape of active site retained (C α RMSD 0.97Å ECH13, 1.5Å ECH19)

- •Cys in designed conformation
- •His not in designed conformation, facilitated by small backbone shift
- •Suggests reason for low overall activity and deacylation problems

In collaboration with A. Kuzin, L. Tong, et al, Northeast Structural Genomics Consortium (NESG)

Esterase design conclusions



•Successfully designed esterase active site into 4 inert scaffolds

- •Scaffolds are structurally unrelated
- → suggests we can design basic esterase catalytic machinery

•Crystal structures of designs and slow deacylation kinetics indicate that the biggest problem is the improperly positioned catalytic histidine

 \rightarrow attempts to improve the activity should thus focus on fixing the histidine position

•Designs are (relatively) bad catalysts but excellent nucleophiles

- \rightarrow Shows that nucleophilicity \neq nucleophilic catalysis
- → Suggest nucleophiles easier to design than catalysts



- Organophosphates (OPs): Chemical warfare agents that inhibit esterases involved in synaptic transmission
- Act by covalently and irreversibly modifying the active site Serine catalytic nucleophile



- •A protein designed to react with OPs faster than native esterases could be used as a scavenger
- •OP binding requires good nucleophile -> cys esterase results suggests design feasible
- •OP transition state (TS) geometry different than ester hydrolysis TS geometry
 - → Designs targeted towards OP-TS might have advantages vs. native esterases



•De novo enzyme design protocol was carried out for organophosphate binding



Theozyme used features a third residue (D/E/H) to ensure histidine is positioned properly

•Experimental setup: in gel screening with a fluorescently labeled OP probe





• ~100 designs made, 4 active, OSH55 is most promising

•Small (165AA), highly expressible, thermophilic scaffold

Crystal structure confirms designed conformation
 → backing up histidine worked

•Knockouts confirm necessity of designed residues for OP binding



OP binding





(Irreversible) OP binding easily accessible to high-throughput yeast display assay
OSH55 library (6 binding site res randomized) was prepared and selected





•Binding was quantified for clones selected from library

• One clone found to react with OP faster than natural esterase!

(with Sridharan Rajagopalan)

De novo Enzyme Design Conclusion



Can new enzymes be designed from scratch computationally?

•good: succesfully done for 5 very different reactions (deprotonation, C-C bond breaking, C-C bond forming, ester bond breaking, OP breakdown)

•less good: activity far below natural enzymes.

→ several factors important for catalysis not modeled yet (differential stabilization, substrate access, dynamics, etc..

→Long way to go till routine de-novo design of efficient catalysts

•However, if targets are picked wisely, useful molecules can be designed

Thanks

Baker Lab

- •Sridharan Rajagopalan
- •Sagar Khare
- •Kai Yu
- •Jasmin Gallaher
- •Alexej Grjasnow
- •Jeremy Mills

Houk Lab @ UCLA

- •Gert Kiss
- •Adam Smith
- •Roger Helgeson
- •Ken Houk

Hilvert Lab @ ETH Zurich

- Rebecca Blomberg
- •Zbigniew Pianowski
- •Don Hilvert

Northeast Structural Genomics Consortium

- Alex Kuzin
- •Liang Tong

Cravatt Lab @ Scripps

- •Eranthie Weerapana
- •Chu Wang
- •Ben Cravatt

Questions?

